Cancer mortality trends after implementation of the national programme for dispensarization of certain groups of the adult population: a population-based study from arkhangelsk, north-western russia

Purpose of the study.To conduct a comparative analysis of the mortality from malignant neoplasms (MNs) detected during the implementation of the oncological component of National Prevention Programme named Dispensarization of certain groups of the adult population (DCGAP) according to the data of the Arkhangelsk Regional Cancer Registry (ARCR) for the period from 2006 to 2019.

Materials and methods. Anonymous data about patients with malignant neoplasms of the colon, rectum, lung, breast, cervix, uterus, ovaries, prostate gland, kidney undergoing examination (screening) at the first stage of the DCGAP from 2006 to 2019 were extracted from the ARCR database. We compared the averaged crude and age-standardized (WHO world standard 2001) mortality rates in the periods before (2006–2012) and after the implementation of DCGAP (2013–2019) in the entire population, as well as in men and women and in age groups 15–59 years old for males and 15–55 years old for the female population ("mortality at working age") and 30–69 years old ("premature mortality"). A segmented analysis of the mortality rates was carried out. The interventional value of the DCGAP was positive in the case of a decrease in the linear trend in mortality between 2013 and 2017.

Results. A total of 33,824 deaths were included in the analysis. 25106 (74.2%) patients died from iMN, the proportion of deaths from other causes varied from 14% for lung cancer to 83% for cervical and prostate cancer. The crude mortality rate after the introduction of DCGAP increased for all iMNs, except for cervical cancer, while age standardized rate only for cancers of the uterus and prostate. In lung cancer, there was a decrease in age-standardized mortality rates for men from 64.7 to 60.3 per 100,000 population and an increase from 5.1 to 6.5 per 100,000 for women. Mortality rates “at working age” were low for all iMNs except for cervical and breast cancers and did not differ between periods; “premature mortality” decreased only in lung cancer in men from 40.1 to 36.2 per 100,000 population, with other iMNs differences between periods were not revealed. Segmented analysis revealed no significant changes in mortality trends.

Conclusion. There was no decrease in mortality among all nine iMNs in the period after the introduction of DCGAP, which is probably due to increased incidence and insufficient follow-up for later period. A comparative analysis of survival is required.

dispensarization of certain groups of the adult population, cancer screening, early diagnosis of cancer, mortality, premature mortality, segmented analysis

1. On national goals and strategic development objectives of the Russian Federation for the period up to 2024. Decree of the President of the Russian Federation No. 204 of 07.05.2018. Available at: http://kremlin.ru/acts/bank/43027. Accessed: 15.07.2020. (In Russian).

2. Population Mortality by major classes and individual causes of death in 2018. Federal state statistics service. Available at: http://www.gks.ru/bgd/regl/b18106/Main.htm. Accessed: 21.07.2020. (In Russian).

3. Passport of the Federal project "Fight against cancer". Available at: https://static-0.minzdrav.gov.ru/system/attachments/attaches/000/046/709/original/FP_Borba_s_onkologicheskimi_zabolevaniyami.pdf?1565344164. Accessed: 15.07.2020. (In Russian).

4. Vishnevsky AG, Shchur AE. Mortality and life expectancy in Russia for half a century. ARGSTEV: news, opinions, training. Bulletin of WSOS. 2019;5(2):10–21. (In Russian). https://doi.org/10.24411/2411-8621-2019-12003

5. Aganbegyan AG. Oncological diseases – the main threat to people's lives in the future. ARGSTEV: news, opinions, training. Bulletin of WSOS. 2019;5(4):43–54. (In Russian). https://doi.org/10.24411/2411-8621-2019-14003

6. Premature mortality. The European portal of health information. World health organization regional office for Europe. Available at: https://gateway.euro.who.int/ru/indicators/h20201-prema-ture-mortality/visualizations/#id=17070&tab=table. Accessed: 22.07.2020. (In Russian).

7. The national strategy for the fight against cancer for the long term until 2030. Available at: http://nop2030.ru/files/2017/11/national-strategy.pdf. Accessed: 22.07.2020. (In Russian).

8. Hakama M, Coleman MP, Alexe D-M, Auvinen A. Cancer screening: evidence and practice in Europe 2008. Eur J Cancer. 2008 Jul;44(10):1404–1413. https://doi.org/10.1016/j.ejca.2008.02.013

9. Smith RA, Andrews KS, Brooks D, Fedewa SA, Manassaram-Baptiste D, Saslow D, et al. Cancer screening in the United States, 2018: A review of current American Cancer Society guidelines and current issues in cancer screening. CA Cancer J Clin. 2018;68(4):297–316. https://doi.org/10.3322/Caac.21446

10. On approval of the procedure for conducting medical examinations of certain groups of the adult population. Order of the Ministry of health of the Russian Federation No. 1006n dated December 3, 2012. Available at: https://www.garant.ru/products/ipo/prime/doc/70255634/. Accessed: 01.07.2019. (In Russian).

11. On approval of the procedure for conducting medical examinations of certain groups of the adult population. Order of the Ministry of health of the Russian Federation No. 36an dated February 3, 2015. Available at: https://www.garant.ru/products/ipo/prime/doc/70783132/. Accessed: 21.07.2020. (In Russian).

12. On approval of the procedure for conducting medical examinations of certain groups of the adult population. Order of the Ministry of health of the Russian Federation No. 869n dated October 26, 2017. Available at: https://www.garant.ru/products/ipo/prime/doc/71730314/. Accessed: 21.07.2020. (In Russian).

13. On approval of the procedure for conducting preventive medical examinations and medical examinations of certain groups of the adult population. Order of the Ministry of health of the Russian Federation of March 13, 2019 No. 124n. Available at: https://www.garant.ru/hotlaw/federal/1270605/. Accessed: 21.07.2020. (In Russian).

14. Order of the Government of the Russian Federation of March 21, 2020 N 710-R "on temporary suspension of the all-Russian medical examination of the adult population of the Russian Federation". The GARANT system. Available at: http://base.garant.ru/73781079/#ixzz6SGyHWExb. Accessed: 21.07.2020. (In Russian).

15. Valkov MYu, Karpunov AA, Coleman MP, Allemani C, Pankratieva AYu, Potekhina EF, et al. The Population Based Cancer Registry as a Resource for Research and Practical Healthcare. Human Ecology. 2017;(5):54–62.

16. Vaktskjold A, Lebedintseva JA, Korotov DS, Tkatsjov AV, Podjakova TS, Lund E. Cancer incidence in Arkhangelskaja Oblast in northwestern Russia. The Arkhangelsk Cancer Registry. BMC Cancer. 2005 Jul 19;5:82. https://doi.org/10.1186/1471-2407-5-82

17. Allemani C, Matsuda T, Di Carlo V, Harewood R, Matz M, Nikšić M, et al. Global surveillance of trends in cancer survial 2000-14 (CONCORD-3): analysis of individual records for 37 513 025 patients diagnosed with one of 18 cancers from 322 population-based registries in 71 countries. Lancet. 2018 17;391(10125):1023–1075. https://doi.org/10.1016/S0140-6736(17)33326-3

18. Valkova LE, Levit ML, Merabishvili VM, Pankrateva AYu, Dubovichenko DM, Agaeva AV, et al. Primary epidemiological evaluation of the effectiveness of the All-National Dispensa-rization as a cancer screening by the data of the Arkhangelsk Regional Cancer Registry. Research and Practical Medicine Journal. 2019;6(4):187–199. (In Russian). https://doi.org/10.17709/2409-2231-2019-6-4-20

19. Ahmad, OB, Boschi-Pinto C, Lopez AD, Murray CJL, Lozano R. Age standardization of rates: a new world standard GPE discussion paper series. WHO. 2001. Available at: https://www.who.int/healthinfo/paper31.pdf. Accessed: 21.07.2020.

20. Joinpoint Regression Program, Version 4.7.0.0. February, 2019; Statistical Research and Applications Branch, National Cancer Institute. Available at: https://surveillance.cancer.gov/joinpoint/

21. Merabishvili VM. Analytical indicator. analysis of the real state of dynamics of mortality of the population of Russia from malignant tumors and changes in its structure. Journal Questions of Oncology. 2019:65(2):205-219. (In Russian).

22. Ellis L, Woods LM, Estève J, Eloranta S, Coleman MP, Rachet B. Cancer incidence, survival and mortality: explaining the concepts. Int J Cancer. 2014 Oct 15;135(8):1774–1782. https://doi.org/10.1002/ijc.28990

23. Siegel RL, Miller KD, Jemal A. Cancer statistics, 2019. CA Cancer J Clin. 2019;69(1):7–34. https://doi.org/10.3322/Caac.21551

24. Zaorsky NG, Churilla TM, Egleston BL, Fisher SG, Ridge JA, Horwitz EM, et al. Causes of death among cancer patients. Ann Oncol. 2017 01;28(2):400–407. https://doi.org/10.1093/annonc/mdw604